Acute Migraine Treatment: Pain Freedom and Guidelines
Goals of and Recommended Approach for Acute Treatment
Acute Migraine Management: Overview and Unmet Needs
Safety and Efficacy of CBD in Patients With TSC
William Rosenfeld, MD: Reducing Concomitant ASM Dosages for Focal Seizures
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.
Raymond Sanchez, MD: Phase 2 Trial Data of Tavapadon in Parkinson Disease
The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.
Donanemab Shows Decline in Alzheimer, Pfizer DMD Study Launched, REM Not Correlated With Seizures
Neurology News Network for the week ending January 16, 2021.
Strategies for Choosing Initial Therapy in MS
Clinical Benefit of Fenfluramine in Dravet Syndrome
Brian Wainger, MD, PhD: Momentum Within the ALS Treatment Landscape
The assistant professor of neurology and anesthesiology at Harvard Medical School discussed the landscape of ALS treatments and his outlook on how the future might evolve.
Leo Petrossian, PhD, MBA: Accelerating Optimization of Epilepsy Management
The CEO of Nile AI spoke to how the newly founded company plans to develop data science techniques to improve the optimization of epilepsy care and management.
Phase 4 ELEVATE Study
Richard B. Lipton, MD: CGRP Receptor-Targeting in the Prevention of Migraine
The director of the Montefiore Headache Center discussed the current landscape of migraine treatments.
OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue
Michael Okun, MD: Long-Term Plan for Modifying Neurologic Device Approval System
The executive director of the Norman Fixel Institute for Neurological Diseases gave his call-to-action on how to change the approval system for neurologic devices for rare diseases.
Brian Wainger, MD, PhD: Future Studies Evaluating Motor Neuron Excitability in ALS
The assistant professor of neurology and anesthesiology at Harvard Medical School detailed the future outlook of ezogabine and whether it may be studied again in patients with ALS.
AUPN Leadership Minute Episode 5: Planning a Faculty Retreat
Episode 5 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Steven Vernino, MD, PhD, of UT Southwestern Medical Center. [WATCH TIME: 4 minutes]
Raymond Sanchez, MD: Phase 3 TEMPO Trials Guide Tavapadon
The chief medical officer of Cerevel Therapeutics detailed the TEMPO trials, a trio of studies that will examine tavapadon in patients with early and late-stage Parkinson disease.
Pavel Klein, MD: Finding the Right AEDs for Patients With Epilepsy
The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to catch refractory epilepsy early and look for the most efficacious treatments for their patients.
FDA Approves EEG System, Neurologic Diagnostic Out-Of-Pocket Costs Rising, Nerivio Safe for Adolescents With Migraine
Neurology News Network for the week ending January 9, 2021.
Future Outlook for Dravet Syndrome
Choosing Cannabidiol or Fenfluramine for Dravet
Approval of Cannabidiol and Fenfluramine for Dravet
Treatment Options for Dravet Syndrome
Importance of Early Diagnosis of Dravet Syndrome
Overview of Dravet Syndrome
William Rosenfeld, MD: Decreasing Concomitant ASM Use With Cenobamate for Epilepsy
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team saw a roughly 25% decrease in the mean use of concomitant ASMs.
Richard B. Lipton, MD: Challenges of Treating Migraine
The director of the Montefiore Headache Center discussed how different treatments work for different patients with migraine.
Todd Levine, MD: Synuclein’s Role in Parkinson Disease Diagnosis
The chief medical officer of CND Life Sciences and medical director of Honor Health Neurology spoke to the role synuclein has played in advancing PD diagnosis.
Michael Okun, MD: Importance of Disease-Based Registries
The executive director of the Norman Fixel Institute for Neurological Diseases explained how disease-based registries play a crucial part in changing the approval system for neurologic devices in rare diseases.
